> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Standard BioTools' Treeline Deal Would Leave Its Holders About 16%, Amended S-4 Shows
- URL: https://www.bullished.co/standard-biotools-treeline-deal-would-leave-its-holders-about-16-amended-s-4-shows-8b4a574e/
- Published: 2026-10-21T10:11:15.000Z
- Updated: 2026-11-05T20:32:15.000Z
- Description: The third amended filing adds a $5.0 million microfluidics sale and an Oct. 16 record date, but the special meeting date is still blank.
- Author: Matteo Parrino
- Tags: Deals, LAB, Industry: Healthcare

[Standard BioTools](https://www.bullished.co/tag/lab/) holders would own about 16% of the combined company after the Treeline Biosciences reverse merger, according to a [third amended S-4](https://www.sec.gov/Archives/edgar/data/0001162194/000114036126040313/ny20077604x7%5Fs4a.htm?ref=bullished.co) filed Wednesday. Treeline holders would own about 84%, fully diluted, and the filing leaves the special meeting date blank.

## What the amendment sets

The exchange ratio is estimated at about [11.1202 to 11.7157](https://www.sec.gov/Archives/edgar/data/0001162194/000114036126040313/ny20077604x7%5Fs4a.htm?ref=bullished.co) Standard BioTools shares per Treeline share, before a reverse split, using capitalization as of Oct. 6, 2026\. Standard BioTools expects to issue up to 1,974,746,335 shares.

The record date for the special meeting is Oct. 16, 2026, when 394,711,296 shares were outstanding and there were 220 holders of record. The board recommends voting FOR every proposal.

The filing adds a $5.0 million sale of the microfluidics business to a buyer formed by ARCHIMED, signed Oct. 4, 2026\. That sale is not conditioned on the merger. It sits alongside the $5.5 million sale of the Element mass cytometry business, which the filing also says is not a merger condition.

The pro forma balance sheet at June 30, 2026 shows total assets of $1,103,365K and stockholders' equity of $1,024,595K. Pro forma net loss from continuing operations was $(248,866)K for 2025 and $(149,145)K for the first six months of 2026.

## What it changes for holders

Shares closed at $0.66 on Oct. 13, 2026, per the filing, against $1.15 on June 5, 2026\. A reverse split of 1-for-20 to 1-for-40 is needed to reach Nasdaq's $4.00 minimum bid for listing.

The ratio is not adjusted for stock-price moves. It does shift if Standard BioTools' net cash lands outside a $449 million to $451 million band. A lower final figure means more shares to Treeline holders, and a surplus goes to holders of contingent value rights.

Those rights carry a cap of 76,000,000 shares and are funded by legacy business sale proceeds and any final net cash surplus.

The filing says Standard BioTools reached the deal after a strategic review found no suitable buyer for its tools business despite talks with more than 15 parties. Its stock had traded below cash for an extended period, and the special committee judged the standalone plan unviable and compared the deal with a wind-down.

## What to watch

The meeting date and the final reverse split ratio are still to be set. The filing lists an outside date of March 31, 2027.

Until the meeting date is filled in, holders have a record date and a ratio range but no vote to mark on a calendar.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [S-4/A — STANDARD BIOTOOLS INC. re: STANDARD BIOTOOLS INC. (LAB)](https://www.sec.gov/Archives/edgar/data/0001162194/000114036126040313/ny20077604x7%5Fs4a.htm?ref=bullished.co) — SEC EDGAR

### More on Standard BioTools

- [Standard BioTools Sells Two Businesses For $10.5 Million, Leaving An $18.6 Million Lease Asset At Risk](https://www.bullished.co/standard-biotools-sells-two-businesses-for-10-5-million-leaving-an-18-6-million-lease-40981004/)
- [Standard BioTools Completes Microfluidics Sale To ARCHIMED, Which Renames It Biomark Scientific](https://www.bullished.co/standard-biotools-completes-microfluidics-sale-to-archimed-which-renames-it-biomark-73fe66d0/)
- [Standard BioTools Holders Would Own About 16% Of Treeline Combination, Amended S-4 Shows](https://www.bullished.co/standard-biotools-holders-would-own-about-16-of-treeline-combination-amended-s-4-shows-bafb0999/)

[All Standard BioTools (LAB) coverage →](https://www.bullished.co/tag/lab/)